Serum FABP1 levels were also significantly higher in patients with moderate-to-severe NALFD (median 3.98 ng/mL, IQR 1.82–6.69 ng/mL) than in those with none-to-mild NAFLD (1.30 ng/mL, IQR 0.49–3.60 ng/mL, p < 0.01) (Figure 1G). Here, FABP1 is linked to metabolic dysfunction-associated steatotic liver disease.